Dexcom Beats Quarterly Sales Expectations, Reaffirms Annual Outlook
Analysts had raised concerns about the pace at which Dexcom was capturing "basal only" diabetes patients who take one insulin injection a day
Written By : Farhat Nasim
Published On 2024-10-27 04:30 GMT | Update On 2024-10-27 04:30 GMT
Advertisement
Bengaluru: Dexcom, a medical device manufacturer, surpassed Wall Street expectations for third-quarter revenue and profit on Thursday, driven by strong demand for its continuous glucose monitors among diabetes patients and increased sales in international markets.
However, shares tumbled as much as 20% in extended trading after the company reiterated its full-year sales forecast and posted a 2% decline in U.S. sales for the quarter, disappointing some investors.
The stock is down 40% this year, largely due to a slump in July after Dexcom slashed its annual revenue forecast, blaming a restructuring of its sales team, fewer customers, and lower revenue from each customer.
CEO Kevin Sayer said in a post-earnings conference call performance would improve in the fourth-quarter and "get more and more effective over time".
Shares recouped some lost ground and were last down 5%.
Sayer also said a record number of new patients signed up in the third quarter after Dexcom implemented feedback from its distribution channels.
The company also improved access to its devices in markets such as Japan and France to reach more "basal only" patients, and expects to see revenue growth in these markets next year.
Analysts had raised concerns about the pace at which Dexcom was capturing "basal only" diabetes patients who take one insulin injection a day, compared to rival Abbott.
Dexcom in August launched its over-the-counter device Stelo in the U.S. for adults aged 18 and older who do not use insulin, making it the first continuous glucose monitor available for over-the-counter sales.
The company reported third-quarter revenue of $994.2 million, beating analysts' estimates of $990.7 million, according to data compiled by LSEG.
On adjusted basis, it earned a profit of 45 cents per share, slightly above expectations of 43 cents.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.